Daiichi Sankyo has signed an investment contract with Cuorips, a spin-off venture established by Osaka University.

This collaboration will give Daiichi Sankyo an option right for the worldwide commercialisation of a new iPS-derived cardiomyocyte sheet developed by Cuorips. The allogeneic cell therapy product can be transplanted to provide improvement of cardiac function and amelioration of heart failure.

“Daiichi Sankyo has invested in the Osaka University spin-off venture Cuorips with the aim of commercialising a new iPS-derived cardiomyocyte sheet.“

It is thought that this innovation has the potential to become an important new treatment option for patients with severe heart failure, who currently have no remedies other than heart transplantation or artificial heart implantation.

A team from Osaka University's department of cardiovascular surgery has been working on the research and development of the new product by participating in the Research Centre Network for Realisation of Regenerative Medicine, which is run by the Japan Agency for Medical Research and Development.

They are currently preparing to commence full clinical research of the cardiomyocyte sheet, with an investigator-initiated clinical study also planned.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.